Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with severe renal impairment or on haemodialysis

BJU International

Volumn 108, Issue 8, 2011, Pages 1279-1283

  Josephs, Debra ^a   Hutson, Thomas E ^e   Cowey, Charles L ^e   Pickering, Lisa M ^b   Larkin, James M ^b   Gore, Martin E ^b   Van Hemelrijck, Mieke ^c   McDermott, David F ^g   Powles, Thomas ^d   Chowdhury, Paramit ^a   Karapetis, Chris ^h   Harper, Peter G ^a   Choueiri, Toni K ^f   Chowdhury, Simon ^a  

^a GUY S HOSPITAL   (United Kingdom)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^e BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^f DANA FARBER CANCER INSTITUTE   (United States)

^g BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^h FLINDERS MEDICAL CENTRE   (Australia)

Author keywords

chronic kidney disease; haemodialysis; renal cell carcinoma; sunitinib

Indexed keywords

SUNITINIB;

ADULT; AGED; ANEMIA; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; DISEASE SEVERITY; DRUG CYTOTOXICITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; GLOMERULUS FILTRATION RATE; HAND FOOT SYNDROME; HEALTH CARE QUALITY; HEMODIALYSIS; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; KIDNEY DYSFUNCTION; LEUKOPENIA; MALE; METASTASIS; NAUSEA AND VOMITING; NEUTROPENIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RASH; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; DISEASE-FREE SURVIVAL; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; INDOLES; KIDNEY FAILURE, CHRONIC; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PYRROLES; RENAL DIALYSIS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 80052406632     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2010.09990.x     Document Type: Article

References (19)

1. Parkin DM, Bray F, Ferlay J, Pisani P,. Global Cancer Statistics, 2002. CA Cancer J Clin 2005; 55: 74-108 (Pubitemid 40372904)
2. Motzer RJ, Hutson TE, Tomczak P, et al,. Sunitinib versus intereron alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356: 115-24 (Pubitemid 46089672)
3. Pfizer Laboratories. Sutent® Sunitinib Maleate Capsules. 2006. Available at: http://www.pfizer.com/files/products/uspi-sutent.pdf. Accessed 9 December 2010
4. Goddard J, Harris K, Turner N,. Chronic Kidney Disease eGuide. Revised January 2009. Available at: http://www.renal.org/whatwedo/InformationResources/ CKDeGUID.aspx. Accessed 9 December 2010
5. Gupta S, Parsa V, Heilbrun L, et al,. Safety and efficacy analysis of sunitinib, bevacizumab, and m-TOR inhibitors in metastatic renal cell cancer patients with renal insufficiency. J Clin Oncol 2009; 27: 15s (suppl; abstr 5108)
6. Miller DC, Schonlau M, Litwin MS, Lai J, Saigal CS,. Renal and cardiovascular morbidity after partial or radical nephrectomy. Cancer 2008; 112: 511-20 (Pubitemid 351186192)
7. Wong G, Hayen A, Chapman JR, et al,. Association of chronic kidney disease and cancer risk in older people. J Am Soc Nephrol 2009; 20: 1341-50
8. Vajdic CM, McDonald SP, McCredie MRE, et al,. Cancer incidence before and after kidney transplantation. JAMA 2006; 296: 2823-831 (Pubitemid 44969182)
9. Stewart JH, Buccianti G, Agodoa L, et al,. Cancers of the kidney and urinary tract in patients on dialysis for end-stage renal disease: analysis of data from the United States, Europe and Australia and New Zealand. J Am Soc Nephrol 2003; 14: 197-207 (Pubitemid 36026310)
10. Gore ME, Szczylik C, Porta C, et al,. Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded access trial. Lancet Oncol 2009; 10: 757-63
11. Lainakis G, Bamias A, Psimenou E, et al,. Sunitinib treatment in patients with severe renal function impairment: a report of four cases by the Hellenic Cooperative Oncology Group. Clin Nephrol 2009; 72: 73-8
12. Park CY,. Successful sunitinib treatment of metastatic renal cell carcinoma in a patient with end stage renal disease on hemodialysis. Anti-Cancer Drugs 2009; 20: 848-9
13. Zastrow S, Froehner M, Platzek I, et al,. Treatment of metastatic renal cell cancer with sunitinib during chronic hemodialysis. Urology 2009; 73: 868-70
14. Izzedine H, Etienne-Grimaldi MC, Renee N, et al,. Pharmacokinetics of sunitinib in haemodialysis. Ann Oncol 2009; 20: 190-2
15. Khosravan R, Toh M, Garrett M, et al,. Pharmacokinetics and safety of sunitinib malate in subjects with impaired renal function. J Clin Pharmacol 2010; 50: 472
16. Motzer RJ, Mazumdar M, Bacik J, et al,. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999; 17: 2530-40 (Pubitemid 29368255)
17. Dreisbach AW, Lertora JJL,. The effect of chronic renal failure on hepatic drug metabolism and drug disposition. Int J Clin Pharmacol Ther 2000; 38: 245-53
18. Parsa V, Heilbrun L, Smith D, Sethi A, Vaishampayan U,. Safety and efficacy of sorafenib therapy in patients with metastatic kidney cancer with impaired renal function. Clin Genitourin Cancer 2009; 7: E10-5
19. Fried LF, Shlipak MG, Crump C, et al,. Renal insufficiency as a predictor of cardiovascular outcomes and mortality in elderly individuals. J Am Coll Cardiol 2003; 41: 1364-72 (Pubitemid 36438998)